Localized and Advanced Stage Follicular Lymphomas Differ in their Gene Expression Profiles.
The genetic background of follicular lymphomas (FL) diagnosed in advanced clinical stages III/IV, frequently characterized by the t(14;18), has been substantially unraveled. Molecular features as exemplified in the m7FLIPI are important tools in risk stratification. In contrast, little information is available concerning localized-stage FL (clinical stages I/II), comprising approximately 20% of newly diagnosed FL in which the t(14;18) detection rate is only ~50%. To investigate the genetic background of localized-stage FL, patient cohorts of both advanced-stage and localized-stage FL, uniformly treated within phase III trials of the German Low-Grade Lymphoma Study Group (GLSG), were comparatively analyzed. Targeted gene expression (GE) profiling of 184 genes using the nCounter technology was performed in 110 localized-stage and 556 advanced-stage FL. By penalized Cox regression, a prognostic GE signature could not be identified in patients with advanced-stage FL, consistent with results from global tests and univariate regression. In contrast, it was possible to define robust GE signatures discriminating localized-stage and advanced-stage FL (AUC: 0.98) by penalized logistic regression. Of note, 3% of samples harboring an 'advanced-stage signature' in the localized-stage cohort demonstrated inferior failure-free survival (hazard ratio, HR, 7.1, p=0.0003). Likewise, in the advanced-stage cohort, 7% of samples with a 'localized-stage signature' had prolonged failure-free (HR 2.3, p=0.017) and overall survival (HR 3.4, p=0.072). These data support the concept of a biological difference between localized-stage and advanced-stage FL that might contribute to the superior outcome of localized FL.